The JIA patients recruited in this study had relatively low levels of disease activity. It could be postulated Dapagliflozin clinical trial that had patients with more active/severe disease been targeted, that the levels of maternal stress would have exceeded those seen in eczema and enteral feeding. The paper by Lederberg and Golbach[18] referenced in our paper regarding maternal stress in mothers of deaf children suggested mothers of deaf children do not feel a high level of parenting stress.

Stress levels were comparable to normative data. In this study they used another tool (Questionnaire on Resources and Stress [QRS-F]) to measure maternal stress in addition to PSI. By the QRS-F tool mothers of deaf children did express more stress. Most of the patients involved in the study had been enrolled in early intervention programs, which may have helped to reduce stress levels. Patients with JIA in the Australian setting are often not as well supported as those with deafness for which established structures of support are in place. The paper by Powers et al.,[19] which reported on parenting stress in young children check details with diabetes, looked more

specifically at parental stress in response to mealtime behavioral problems. In their paper the level of parental stress measured by PSI Total Stress score was higher in parents of diabetics (218.1) when compared to a control group (195.5) recruited in the study. Thus the Powers et al. paper did not use the established normative data for PSI Total Stress score, which others[14] and us have used as a comparator. In fact if we Idoxuridine were to use the lower 195.5 score rather than 222 it would further strengthen the findings of increased stress in the mothers of children with JIA and further highlights the need for intervention in parents of children with chronic illness, as it appears

to alleviate stress. The literature including Caning et al.[12] regarding outcomes of mothers of children with chronic disease generally agrees that disease severity is not related to psychological outcome. There was not a significant association between current disease activity and maternal stress levels in this study. The overall disease activity was not high with low mean active joint counts, CHAQ scores indicating mild disease activity and low mean physician global assessments. However, half of the patients were taking a disease-modifying anti-rheumatic drug (DMARD) and one-fifth a biologic DMARD, which would suggest that at some point in time the disease activity in at least some of the patients included had been greater. The low levels of disease activity seen in this study were not surprising. Current treatment practices for JIA and all the inflammatory arthritides in general aim for remission and even low levels of disease activity are not accepted. The mothers in this study were recruited at any stage of their child’s disease course.